Hormonal
Rosiglitazone treatment (4 mg twice daily for 10-12 weeks) improves whole-body insulin sensitivity in patients with type 2 diabetes by enhancing the insulin sensitivity of peripheral adipocytes, which reduces plasma fatty acid concentrations and redistributes triglycerides from the liver and muscle to subcutaneous adipose tissue.
For patients with type 2 diabetes, rosiglitazone (4mg twice daily) significantly improves how the body uses insulin. It works by making fat cells more sensitive to insulin, which lowers fatty acids in the blood and moves stored fat out of the liver and muscles into safe fat stores. This improves blood sugar control without necessarily changing body weight or intramuscular fat levels.
In conclusion, these results support the hypothesis that thiazolidinediones enhance insulin sensitivity in patients with type 2 diabetes by promoting increased insulin sensitivity in peripheral adipocytes, which results in lower plasma fatty acid concentrations and a redistribution of intracellular lipid from insulin responsive organs into peripheral adipocytes.
Why this rating
Randomized controlled trial design with rigorous metabolic clamps and NMR spectroscopy, though the sample size is small (n=9).
Source
The Effects of Rosiglitazone on Insulin Sensitivity, Lipolysis, and Hepatic and Skeletal Muscle Triglyceride Content in Patients With Type 2 Diabetes
Adam B. Mayerson et al. · Diabetes · 2002
DOI 10.2337/diabetes.51.3.797
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →